Loading...
•
Mar 31, 2020
Penumbra Q1 2020 Earnings Report
Reported a revenue increase of 6.9% driven by vascular products, but neuro products declined slightly.
Key Takeaways
Penumbra, Inc. reported a 6.9% increase in revenue for the first quarter of 2020, reaching $137.3 million. The growth was primarily driven by vascular products, while neuro products experienced a slight decline. Operating income decreased compared to the previous year.
Total revenue grew to $137.3 million, a 6.9% increase over Q1 2019.
Vascular product revenue increased by 26.2%.
Neuro product revenue declined by 4.2%.
Operating income decreased to $0.6 million, compared to $11.2 million in Q1 2019.
Revenue by Geographic Location
Forward Guidance
Due to the uncertain scope and duration of the pandemic, and uncertain timing of global recovery and economic normalization, Penumbra cannot, at this time, reliably estimate the future impact on our operations and financial results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...